

# Niki Karachaliou

## List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/3534077/publications.pdf](https://exaly.com/author-pdf/3534077/publications.pdf)

Version: 2025-02-01

83

PR articles

4,311

PR citations

105543

32

PR h-index

86065

64

g-index

109

documents

5952

doc citations

79788

38

h-index

12105

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non-Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns. <i>Clinical Cancer Research</i> , 2024, 30, 4822-4833.	6.9	8
2	Spatial profiling of METex14-altered NSCLC under tepotinib treatment: Shifting the immunosuppressive landscape. <i>Neoplasia</i> , 2024, 57, 101063.	7.2	1
3	Overcoming MET-mediated resistance in oncogene-driven NSCLC. <i>iScience</i> , 2023, 26, 107006.	3.6	10
4	BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100113.	1.0	5
5	Mechanisms of resistance to osimertinib. <i>Journal of Thoracic Disease</i> , 2020, 12, 2851-2858.	1.3	83
6	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 416-425.	2.2	17
7	Novel molecular targets for the treatment of lung cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 37-43.	2.2	23
8	Proprotein convertase furin in SARS-CoV-2 and non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 945-947.	2.1	2
9	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1810-1821.	2.1	14
10	SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations. <i>iScience</i> , 2020, 23, 101832.	3.6	15
11	Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, .	2.8	10
12	Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100084.	1.0	2
13	Characterising acquired resistance to erlotinib in non-small cell lung cancer patients. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1019-1028.	2.5	13
14	<p></p>Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives<p></p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4567-4575.	1.7	22
15	Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions. <i>Molecular Oncology</i> , 2019, 13, 2633-2645.	4.2	85
16	Targeting PKC $\delta$ -PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. <i>Cell Communication and Signaling</i> , 2019, 17, .	8.1	27
17	BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. <i>Cancers</i> , 2019, 11, 1381.	4.0	57
18	Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines. <i>Translational Lung Cancer Research</i> , 2019, 8, 340-351.	2.1	16

#	ARTICLE	IF	PR CITATIONS
19	Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP). <i>Thoracic Cancer</i> , 2019, 10, 508-518.	2.0	10
20	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.	2.2	115
21	Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP). <i>Frontiers in Oncology</i> , 2019, 9, .	2.7	26
22	Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 167-177.	2.8	48
23	Targeting PKC $\delta$ -PAK1 in EGFR-mutation positive non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 667-673.	2.1	13
24	Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC). <i>International Journal of Biological Sciences</i> , 2019, 15, 2607-2614.	8.8	30
25	Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC). <i>EBioMedicine</i> , 2019, 39, 207-214.	9.9	43
26	Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. <i>Cancer Research</i> , 2019, 79, 546-556.	0.6	77
27	Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. <i>Melanoma Research</i> , 2018, 28, 195-203.	1.5	22
28	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, .	3.8	111
29	RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 474-479.	2.5	21
30	Clinical assessment of immune-related adverse events. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, .	3.8	125
31	Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis. <i>EBioMedicine</i> , 2018, 29, 112-127.	9.9	74
32	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, .	3.8	246
33	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, .	3.8	116
34	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. <i>Translational Lung Cancer Research</i> , 2018, 7, 691-702.	2.1	11
35	ARID1A Gene Driver Mutations in Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2018, 13, e255-e257.	2.2	28
36	Activation of viral defense signaling in cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, .	3.8	18

#	ARTICLE	IF	PR CITATIONS
37	Anti-epidermal growth factor vaccine antibodies enhance the efficacy of tyrosine kinase inhibitors and delay the emergence of resistance in EGFR mutant lung cancer cells. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1324-1337.	2.2	34
38	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1021-1030.	2.6	28
39	The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring. <i>Current Oncology Reports</i> , 2018, 20, .	4.4	64
40	Response to crizotinib in a non-small-cell lung cancer patient harboring an <i>EML4-ALK</i> fusion with an atypical <i>LTBP1</i> insertion. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1117-1120.	1.7	4
41	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 771-781.	24.2	196
42	An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 35-45.	3.2	42
43	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 295-304.	2.2	12
44	Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Chemistry</i> , 2017, 63, 751-760.	1.1	66
45	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. <i>British Journal of Cancer</i> , 2017, 116, 802-810.	5.7	140
46	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	24.2	179
47	Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 713-722.	4.0	19
48	Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP). <i>Targeted Oncology</i> , 2017, 12, 513-523.	3.3	25
49	Using genetics to predict patient response to platinum-based chemotherapy. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 21-32.	0.9	7
50	Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. <i>Cancer Treatment Reviews</i> , 2017, 60, 1-11.	9.8	36
51	Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. <i>Cancer Cell</i> , 2017, 32, 238-252.e9.	38.5	303
52	Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2047-2063.	4.5	33
53	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 109-125.	2.0	63
54	Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2017, 8, 47305-47316.	1.7	46

#	ARTICLE	IF	PR CITATIONS
55	Possible application of circulating free tumor DNA in non-small cell lung cancer patients. Journal of Thoracic Disease, 2017, 9, S1364-S1372.	1.3	14
56	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget, 2016, 7, 1066-1075.	1.7	194
57	Human endogenous retroviruses and cancer. Cancer Biology and Medicine, 2016, 13, 483.	4.9	98
58	Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report. Translational Lung Cancer Research, 2016, 5, 532-537.	2.1	5
59	Annual or biennial lung cancer CT screening?. Journal of Thoracic Disease, 2016, 8, 2424-2426.	1.3	4
60	Unraveling the genomic complexity of small cell lung cancer. Translational Lung Cancer Research, 2016, 5, 363-366.	2.1	35
61	Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients. Translational Lung Cancer Research, 2016, 5, 525-531.	2.1	23
62	Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. OncoTargets and Therapy, 2016, Volume 9, 6361-6376.	1.7	21
63	Liquid Biopsy in Non-Small Cell Lung Cancer. Frontiers in Medicine, 2016, 3, .	2.6	54
64	Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma. Pulmonary Therapy, 2016, 2, 1-18.	2.8	2
65	<i>SMARCA4</i> / <i>BRG1</i> Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 2396-2404.	6.9	137
66	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	2.2	173
67	Feasibility of Cell-Free Circulating Tumor DNA Testing for Lung Cancer. Biomarkers in Medicine, 2016, 10, 417-430.	1.6	24
68	HER3 as a Therapeutic Target in Cancer. BioDrugs, 2016, 31, 63-73.	6.5	33
69	Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response. Oncotarget, 2016, 7, 56619-56627.	1.7	17
70	Immune checkpoint blockade (ICB) for first line treatment in non-small cell lung cancer (NSCLC). Translational Cancer Research, 2016, 5, S408-S410.	1.3	3
71	BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Research, 2015, 25, 486-495.	1.5	78
72	Association of <i>EGFR</i> L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncology, 2015, 1, 149.	14.6	235

#	ARTICLE	IF	PR CITATIONS
73	Relationship between gene mutation and lung cancer metastasis. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 243-248.	7.2	22
74	Pharmacogenomics in the Treatment of Lung Cancer: an Update. <i>Pharmacogenomics</i> , 2015, 16, 1751-1760.	1.6	6
75	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK <sup>+</sup> positive lung cancer. <i>Nature Medicine</i> , 2015, 21, 1038-1047.	39.5	282
76	Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 807-815.	2.6	19
77	The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i> -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. <i>Clinical Cancer Research</i> , 2014, 20, 2001-2010.	6.9	227
78	Signaling Pathways Modulating Dependence of Lung Cancer on Mutant Epidermal Growth Factor Receptor and Mechanisms of Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors. <i>Current Pharmaceutical Design</i> , 2014, 20, 3883-3893.	2.4	6
79	Genetics and biomarkers in personalisation of lung cancer treatment. <i>Lancet, The</i> , 2013, 382, 720-731.	52.8	286
80	KRAS Mutations in Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 205-214.	2.8	219
81	BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients with EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2013, 8, 295-300.	2.2	17
82	Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOP2A, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide. <i>PLoS ONE</i> , 2013, 8, e74611.	2.4	32
83	Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non-Small-Cell Lung Cancer Pretreated With Non-Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study. <i>Clinical Lung Cancer</i> , 2011, 12, 100-105.	2.8	6